Cell and gene therapies: why advanced medicines call for specialised logistics
Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But…
Sponsored
Latest in
Sponsored
Partner content
A digital twin for the body: why patient data consent is vital
Data gathered from numerous digital touchpoints and interactions may create a complete digital twin for the human body in the…
Partner content
From operator to API: how the future of micronisation means no more compromise
Despite industry investment in large molecule drugs, demand for small molecule active pharmaceutical ingredients (API) manufacturing remains high. Driven by…
Partner content
Untapped opportunity: the growing potential of clinical trials in Georgia
In the wake of Russia’s invasion of Ukraine, sponsors are increasingly evaluating other European countries to conduct their clinical trials.…
Partner content
How Syngene helped develop the world’s first drug for a rare disease affecting children
Syngene partnered with a company to develop and manufacture a first-in-class treatment for a rare disease affecting children.
Partner content
Enabling the next wave of innovative drug therapies with speciality enzymes
Approximately 75,000 enzymes are thought to exist in the human body as vital catalysts for biochemical reactions or conversions. For…
Partner content
Moving off the critical path: Streamlining strategies for drug substance synthesis and manufacturing
Each molecule has unique requirements and challenges, and a variety of solutions for drug substance synthesis and manufacturing are available,…
Partner content
Unlocking the potential of direct-to-patient as decentralised trials continue to grow
The global healthcare and pharmaceutical industry is frequently faced with having to find new ways of innovating and carrying out…